Virus and drug combo takes on tough cancers

NCT ID NCT07185243

Recruiting now Disease control Sponsor: Hangzhou Converd Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tests a new combination therapy for people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses a modified virus (hV01) designed to infect and kill cancer cells while boosting the immune system, plus an immunotherapy drug (tislelizumab) that helps the immune system attack the cancer. The trial will enroll 24 participants to check safety and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a modified virus (hV01) that carries an immune-boosting protein, plus an immunotherapy drug (tislelizumab)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to standard therapies.
What could go wrong: This is a very early, small trial (24 people) focused mainly on safety. The combination may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Xiamen Humanity Hospital
RECRUITING

Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.